Actinium Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Developments and Strategic Partnerships

JonesTrading analyst Justin Walsh has maintained their bullish stance on ATNM stock, giving a Buy rating on March 10.

Justin Walsh has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ potential for growth. The initiation of a Phase I trial involving Actimab-A, in collaboration with the National Cancer Institute, is a significant development. This trial, targeting newly diagnosed acute myeloid leukemia, could expand Actinium’s market opportunities beyond the relapsed or refractory setting, where current estimates already show promising sales potential.
Despite previous setbacks with the Iomab-B regulatory process in the U.S., the company’s strategic focus on Actimab-A and its partnership with Immedica for European approval provide a positive outlook. The valuation of Actinium’s stock, with a price target of $9, is supported by a risk-adjusted discounted cash flow analysis, considering cash flows projected through 2032. This assessment, combined with favorable clinical and regulatory updates, underpins the Buy rating.

In another report released on March 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.